JP2023516291A5 - - Google Patents
Info
- Publication number
- JP2023516291A5 JP2023516291A5 JP2022551377A JP2022551377A JP2023516291A5 JP 2023516291 A5 JP2023516291 A5 JP 2023516291A5 JP 2022551377 A JP2022551377 A JP 2022551377A JP 2022551377 A JP2022551377 A JP 2022551377A JP 2023516291 A5 JP2023516291 A5 JP 2023516291A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- pharmaceutical composition
- inhibitor
- composition according
- estrogen receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025090731A JP2025131656A (ja) | 2020-03-06 | 2025-05-30 | エストロゲン受容体関連疾患の治療方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062985929P | 2020-03-06 | 2020-03-06 | |
| US62/985,929 | 2020-03-06 | ||
| PCT/US2021/021151 WO2021178846A1 (en) | 2020-03-06 | 2021-03-05 | Methods of treating estrogen receptor-associated diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025090731A Division JP2025131656A (ja) | 2020-03-06 | 2025-05-30 | エストロゲン受容体関連疾患の治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023516291A JP2023516291A (ja) | 2023-04-19 |
| JP2023516291A5 true JP2023516291A5 (https=) | 2024-03-14 |
| JP7708772B2 JP7708772B2 (ja) | 2025-07-15 |
Family
ID=77613854
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022551377A Active JP7708772B2 (ja) | 2020-03-06 | 2021-03-05 | エストロゲン受容体関連疾患の治療方法 |
| JP2025090731A Pending JP2025131656A (ja) | 2020-03-06 | 2025-05-30 | エストロゲン受容体関連疾患の治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025090731A Pending JP2025131656A (ja) | 2020-03-06 | 2025-05-30 | エストロゲン受容体関連疾患の治療方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230129598A1 (https=) |
| EP (1) | EP4114391B1 (https=) |
| JP (2) | JP7708772B2 (https=) |
| KR (1) | KR20220151616A (https=) |
| CN (1) | CN115175679A (https=) |
| AU (1) | AU2021230588A1 (https=) |
| CA (1) | CA3169679A1 (https=) |
| ES (1) | ES3044433T3 (https=) |
| MX (1) | MX2022010425A (https=) |
| WO (1) | WO2021178846A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021003440A2 (pt) | 2018-09-07 | 2021-05-18 | Sanofi | sais de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil) pirrolidin-3-il]oxifenil]-8,9-di-hidro-7h-benzo[7]anuleno-2-carboxilato de metila e seu processo de preparação |
| KR20220034129A (ko) * | 2019-07-07 | 2022-03-17 | 올레마 파마슈티컬스 인코포레이티드 | 에스트로겐 수용체 길항제 요법 |
| EP4037768B1 (en) | 2019-10-01 | 2023-10-11 | Sanofi | Novel substituted 6,7-dihydro-5h-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof |
| AU2020399168A1 (en) | 2019-12-09 | 2022-07-28 | Sanofi | Crystalline form of a 7H-benzo[7]annulene-2-carboxylic acid derivative |
| TW202146007A (zh) * | 2020-02-27 | 2021-12-16 | 法商賽諾菲公司 | 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合 |
| TW202233572A (zh) | 2020-10-19 | 2022-09-01 | 法商賽諾菲公司 | 新穎之經取代的6,7-二氫-5h-苯並[7]輪烯衍生物，其製備方法及其治療用途 |
| WO2022084280A1 (en) | 2020-10-19 | 2022-04-28 | Sanofi | Substituted 6,7-dihydro-5h-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof |
| TWI808648B (zh) * | 2021-02-16 | 2023-07-11 | 美商建南德克公司 | 使用包含gdc-9545及gdc-0077之組合療法治療乳癌 |
| TW202304424A (zh) * | 2021-04-12 | 2023-02-01 | 法商賽諾菲公司 | 包含依維莫司和安森司群的組合 |
| TW202304425A (zh) * | 2021-04-12 | 2023-02-01 | 法商賽諾菲公司 | 包含瑞博西尼和安森司群（ａｍｃｅｎｅｓｔｒａｎｔ）的組合 |
| TW202333704A (zh) * | 2021-11-12 | 2023-09-01 | 大陸商先聲藥業有限公司 | 用於治療腫瘤的藥物組合及其應用 |
| CA3243621A1 (en) * | 2022-02-01 | 2023-08-10 | Eli Lilly And Company | METHODS FOR PREPARING SELECTIVE ESTROGEN RECEPTOR DEGRADING AGENTS |
| US12330304B2 (en) * | 2022-02-02 | 2025-06-17 | Intrinsic Innovation Llc | Object placement |
| WO2023221123A1 (en) * | 2022-05-20 | 2023-11-23 | Olema Pharmaceuticals, Inc. | Crystalline forms of an estrogen receptor antagonist |
| WO2023221122A1 (en) * | 2022-05-20 | 2023-11-23 | Olema Pharmaceuticals, Inc. | Salts and solid forms of an estrogen receptor antagonist |
| WO2024015506A1 (en) * | 2022-07-14 | 2024-01-18 | Olema Pharmaceuticals, Inc. | Methods of treating estrogen receptor-mediated disorders |
| CN114933558B (zh) * | 2022-07-26 | 2022-11-22 | 常熟药明康德新药开发有限公司 | 手性硝基化合物催化还原制备手性氨基化合物的方法 |
| JP2025533900A (ja) * | 2022-10-05 | 2025-10-09 | オレマ ファーマシューティカルズ， インコーポレイテッド | エストロゲン受容体媒介性障害を治療する方法 |
| WO2024076633A1 (en) * | 2022-10-05 | 2024-04-11 | Olema Pharmaceuticals, Inc. | Methods of treating estrogen receptor-mediated disorders |
| CN115872996B (zh) * | 2023-02-21 | 2023-05-05 | 山东绿叶制药有限公司 | 一种雌激素受体降解剂化合物及其制备方法和应用 |
| WO2025106890A1 (en) * | 2023-11-17 | 2025-05-22 | Olema Pharmaceuticals, Inc. | Salts and solid forms of an estrogen receptor antagonist |
| TW202543650A (zh) | 2024-03-08 | 2025-11-16 | 美商海爾達醫療運營公司 | 異雙官能化合物及其在治療疾病中之用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010138659A1 (en) | 2009-05-27 | 2010-12-02 | Ptc Therapeutics, Inc. | Methods for treating brain tumors |
| CA2819299A1 (en) | 2010-12-24 | 2012-06-28 | Merck Sharp & Dohme B.V. | N-substituted azetidine derivatives |
| EP2791128A4 (en) | 2011-12-16 | 2015-04-22 | Olema Pharmaceuticals Inc | NOVEL BENZOPYRAN COMPOUNDS, COMPOSITIONS AND USES THEREOF |
| UY35590A (es) | 2013-05-28 | 2014-11-28 | Astrazeneca Ab | Nuevos compuestos para el tratamiento del cáncer |
| SG11201607339VA (en) * | 2014-03-13 | 2016-10-28 | Hoffmann La Roche | Methods and compositions for modulating estrogen receptor mutants |
| ES3055185T3 (en) | 2014-03-28 | 2026-02-10 | Univ Duke | Treatment of an estrogen receptor positive breast cancer using a selective estrogen receptor modulator |
| TWI874834B (zh) * | 2014-12-18 | 2025-03-01 | 瑞士商赫孚孟拉羅股份公司 | 四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途 |
| KR20250152679A (ko) * | 2015-04-29 | 2025-10-23 | 래디어스 파마슈티컬스, 인코포레이티드 | 암을 치료하는 방법 |
| KR20240142622A (ko) | 2015-10-01 | 2024-09-30 | 올레마 파마슈티컬스 인코포레이티드 | 테트라히드로-1H-피리도[3,4-b]인돌 항에스트로겐 약물 |
| EP3585394A4 (en) | 2017-02-23 | 2021-06-30 | Olema Pharmaceuticals, Inc. | COMPOSITIONS AND PROCEDURES FOR REGULATING IMMUNE SYSTEM ACTIVITY |
| CR20200621A (es) | 2018-06-21 | 2021-02-03 | Hoffmann La Roche | Formas sólidas de 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3 fluoropropil)azetidin-3-il)amino)fenil)-3-(metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)-2,2-difluoropropan-1-ol y procesos para preparar compuestos tricíclicos fusionados que comprenden un resto fenilo o piridinilo sustituido, incluidos métodos para su uso |
| TW202011966A (zh) * | 2018-07-23 | 2020-04-01 | 瑞士商赫孚孟拉羅股份公司 | 用pi3k抑制劑gdc-0077治療癌症之方法 |
| JP7571006B2 (ja) * | 2018-08-17 | 2024-10-22 | ジェネンテック， インコーポレイテッド | 乳がんの処置のための診断的および治療的方法 |
-
2021
- 2021-03-05 CA CA3169679A patent/CA3169679A1/en active Pending
- 2021-03-05 EP EP21763872.5A patent/EP4114391B1/en active Active
- 2021-03-05 MX MX2022010425A patent/MX2022010425A/es unknown
- 2021-03-05 JP JP2022551377A patent/JP7708772B2/ja active Active
- 2021-03-05 AU AU2021230588A patent/AU2021230588A1/en active Pending
- 2021-03-05 US US17/908,941 patent/US20230129598A1/en active Pending
- 2021-03-05 CN CN202180016388.2A patent/CN115175679A/zh active Pending
- 2021-03-05 KR KR1020227030151A patent/KR20220151616A/ko active Pending
- 2021-03-05 ES ES21763872T patent/ES3044433T3/es active Active
- 2021-03-05 WO PCT/US2021/021151 patent/WO2021178846A1/en not_active Ceased
-
2025
- 2025-05-30 JP JP2025090731A patent/JP2025131656A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023516291A5 (https=) | ||
| CN101378743B (zh) | 以2-氨基-1,3-丙二醇衍生物为有效成分的炎症性肠疾病治疗剂及其在制备治疗或预防炎症性肠疾病的药物中的用途 | |
| JP6684210B2 (ja) | チロシン誘導体及びそれを含む組成物 | |
| JP2020176156A (ja) | Ｔｏｌｌ様受容体モジュレーターの固体形態 | |
| JP2022540421A5 (https=) | ||
| EP1772145A1 (en) | Method of effectively using medicine and method concerning prevention of side effect | |
| JP2004507465A5 (https=) | ||
| JP2019533670A5 (https=) | ||
| EP3177311B1 (en) | Drug combinations of cabozantinib with proteasome inhibitor to treat multiple myeloma | |
| JP2013501731A5 (https=) | ||
| TW202333675A (zh) | 用於治療癌症之組合療法之用途 | |
| CN101277687B (zh) | 以2-氨基-1,3-丙二醇衍生物作为有效成分的肝脏疾病治疗剂及肝脏疾病治疗方法 | |
| JP2020523317A5 (https=) | ||
| JP2023503167A5 (https=) | ||
| WO2020167990A1 (en) | Formulations comprising heterocyclic protein kinase inhibitors | |
| JP2019516726A5 (https=) | ||
| CN112512516A (zh) | 用于在已经经历造血干细胞移植的患者中抑制血液恶性肿瘤复发的活性剂 | |
| JP2013525290A5 (https=) | ||
| CN105616411A (zh) | 治疗结肠癌的组合物及其应用 | |
| JP2005512996A5 (https=) | ||
| TWI709402B (zh) | 西達本胺與依西美坦在製備用於治療乳腺癌的聯合用藥物中的用途及聯合用藥物 | |
| JPH09506902A (ja) | 前立線癌の化学療法剤の補助剤 | |
| CN1505511A (zh) | 吡啶并吲哚酮类衍生物用于制备药物的用途 | |
| JP4598674B2 (ja) | 統合失調症治療剤 | |
| WO2024246824A1 (en) | Methods and modified dosing regimens comprising a cdk4 inhibitor for the treatment of cancer |